Population Pharmacokinetics of Lamivudine in Adult Human Immunodeficiency Virus-Infected Patients Enrolled in Two Phase III Clinical Trials

Lamivudine population pharmacokinetics were investigated by using nonlinear mixed-effect modelling (NONMEM) analysis of data from 394 human immunodeficiency virus (HIV)-infected patients treated with lamivudine (150 to 300 mg every 12 h) in two large, phase III clinical efficacy-safety trials, NUCA3...

Cijeli opis

Bibliografski detalji

Izdano u:	Antimicrob Agents Chemother
Glavni autori:	Moore, Katy H. P., Yuen, Geoffrey J., Hussey, Elizabeth K., Pakes, Gary E., Eron, Joseph J., Bartlett, John A.
Format:	Artigo
Jezik:	Inglês
Izdano:	American Society for Microbiology (ASM) 1999
Teme:	Antiviral Agents
Online pristup:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC89609/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/10582904/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.43.12.3025
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!